There were 781 press releases posted in the last 24 hours and 401,622 in the last 365 days.

Avinger, Inc. to Announce Second Quarter 2016 Results on Monday, August 1, 2016

Conference call scheduled for Monday, August 1, 2016 at 1:30pm PT/4:30pm ET

REDWOOD CITY, Calif., July 25, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it will release its financial results for the second quarter of 2016 after the close of trading on Monday, August 1, 2016. The Company will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET.

Individuals interested in listening to the conference call may do so by dialing (844) 776-7820 for domestic callers or (661) 378-9536 for international callers and referencing Conference ID: 53949228. To listen to a live webcast, please visit the investor relations section of Avinger's website at: www.avinger.com

A replay of the call will be available beginning August 1, 2016 at 4:30pm PT/7:30pm ET through midnight on August 2, 2016. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 53949228. The webcast will also be available on Avinger's website for one year following the completion of the call.

About Avinger, Inc.
Avinger, Inc. is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems for the treatment of patients with peripheral artery disease (PAD). PAD is characterized by a build-up of plaque in the arteries that supply blood to the legs and feet. The company’s mission is to dramatically improve the treatment of vascular disease through the introduction of products based on its Lumivascular Platform, the only intravascular image-guided system of therapeutic catheters available in this market. Avinger’s current Lumivascular products include the Lightbox™ imaging console, the Ocelot™ family of catheters, which are designed to penetrate total arterial blockages, known as chronic total occlusions, or CTOs, and Pantheris™, the first-ever image-guided atherectomy device, designed to precisely remove arterial plaque in PAD patients. For more information, please visit www.avinger.com.

“Avinger,” “Lumivascular,” “Lightbox,” “Ocelot,” “Pantheris” and the Avinger logo are registered trademarks of Avinger, Inc.

Investor Contact:
Matt Ferguson
Avinger, Inc.
(650) 241-7917
ir@avinger.com

Primary Logo

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.